ArticleOphthalmology science2023

Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma.

Yang Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.